Gresonitamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - AMG 910 - AMG-910 - AMG910 - BiTE Antibody AMG 910 - Bispecific Antibody AMG 910 - Bispecific T-cell Engager AMG 910 - Bispecific T-cell Engager Antibody AMG 910 - GRESONITAMAB